Investigating how MS4A7 affects tumor resistance to immunotherapy
MS4A7 in tumor resistance to immunotherapy
This study is looking at a protein called MS4A7 in immune cells that are found in tumors to see how it affects the success of cancer treatments, with the hope of finding new ways to make immunotherapy work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11046677 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific protein, MS4A7, found in tumor-associated macrophages (TAMs) and its impact on the effectiveness of immunotherapy in cancer treatment. By studying both human tumors and animal models, the researchers aim to uncover how MS4A7 contributes to immune resistance against cancer therapies. The project will explore the interactions between MS4A7 and other immune-related proteins, potentially identifying new targets for treatment that could enhance the efficacy of immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who are undergoing or considering immunotherapy.
Not a fit: Patients with non-solid tumors or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies for cancer patients, enhancing their chances of effective treatment.
How similar studies have performed: Previous research has shown promising results in targeting immune resistance mechanisms in cancer, suggesting that this approach could lead to significant advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Zou, Weiping — University of Michigan at Ann Arbor
- Study coordinator: Zou, Weiping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.